Drug Trial Radar · NCT06631989
A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
60
Actual
Start
Sep 4, 2024
Primary completion
Jun 30, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Wayshine Biopharm, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 8, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multicenter, open label, single-arm phase I/II clinical trial of WSD0922-FU for patients with locally advanced or metastatic non-small cell lung cancer whose disease has progressed with thrid-generation EGFR-TKI .
Conditions
- EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer
Interventions
WSD0922-FUDrug
Procedure: Biospecimen Collection - blood samples Undergo collection of blood samples Procedure: Computed Tomography and/or Magnetic Resonance Imaging Undergo CT and/or MRI Drug: WSD0922-FU Given PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- ORR by IRCTime frame: every 6 weeks, up to 1 year
- PartA: To evaluate the safety of WSD0922-FU in patients with NSCLCTime frame: 8 months
- PartA: To evaluate the tolerability of WSD0922-FU in patients with NSCLCTime frame: 8 months
- PartA: To evaluate the Maximum Tolerated Dose (MTD) of WSD0922-FU in patients with NSCLCTime frame: 8 months
- PartA: Recommended Phase II Dose (RP2D) of WSD0922-FU in patients with NSCLCTime frame: 8 months
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Anhui Provincial Hospital
Hefei, Anhui, China
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
The First Affiliated Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China
He'nan Cancer Hospital
Zhengzhou, Henan, China
Shandong Cancer Hospital
Jinan, Shandong, China
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China
Shanghai East Hospital
Shanghai, Shanghai Municipality, China
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China
Sichuan Provincial Cancer Hospital
Chengdu, Sichuan, China
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Taizhou Hospital of Zhejiang Province
Taizhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.